Core Insights - The National Health Commission of China announced that the probiotic strain YLGB-1496, developed by the National Dairy Technology Innovation Center in collaboration with Yili, has been included in the list of probiotics suitable for infant food, marking the first domestically developed strain for this purpose in China [1][3] Group 1: Industry Impact - The approval of YLGB-1496 represents a significant breakthrough for the domestic probiotic industry in China, reducing reliance on imported probiotics for infants [3] - YLGB-1496 is designed to efficiently utilize human milk oligosaccharides (HMO), which are crucial for the gut microbiota of breastfed infants, thus helping to establish a healthy early gut microecological system [3] Group 2: Research and Development - A series of rigorous clinical studies on infants have been conducted by Yili in collaboration with the National Dairy Technology Innovation Center and other authoritative institutions, leading to the granting of 15 Chinese invention patents related to this strain and its technology [3][4] Group 3: Commercialization - Jinqi Biotechnology, a platform under Yili with a national-level probiotic industrialization production demonstration line, is responsible for the industrialization and commercialization of YLGB-1496, supporting the upgrade of the health food industry towards high quality and diversification [4] - The strain has already been successfully applied in various products, including QQ Star's "Jianhu Mama," Jinhu Cheese Sticks, and Meiyitian Mixed Fruit and Vegetable Juice, with plans for broader application in infant formula and other core product lines [4]

Core Insights - YLGB-1496, a probiotic strain developed by Yili, has been included in the list of probiotics approved for infant food by the National Health Commission of China, marking a significant breakthrough in the domestic probiotic industry [1][3] Group 1: Probiotic Development - YLGB-1496 is the first probiotic strain in the list that is independently developed by a Chinese dairy company and derived from healthy human breast milk [1][3] - The strain is designed to be more compatible with the physical needs of Chinese infants, providing a tailored probiotic solution [1][3] Group 2: Scientific Validation - Clinical studies conducted in collaboration with the National Dairy Technology Innovation Center have shown that YLGB-1496 significantly reduces the incidence of eczema and respiratory infections in infants, aiding in the development of their immune systems [3] - The strain has also been proven to enhance gut comfort in infants, reducing the occurrence and severity of diarrhea symptoms [3] Group 3: Commercialization and Future Plans - Yili's subsidiary, Jinqi Biotechnology, is responsible for the industrial production and commercialization of YLGB-1496, supporting the upgrade of the health food industry towards high quality and diversification [4] - The strain has already been incorporated into several products, including QQ Star's maternal care products and mixed fruit and vegetable juices, with plans for broader application in infant formula [4] - The approval of YLGB-1496 signifies a major leap for China's dairy industry from technology following to independent innovation in the probiotic sector [4]

Core Insights - YLGB-1496, a probiotic strain developed by Yili, has been included in the list of probiotics approved for infant food by the National Health Commission of China, marking a significant breakthrough in the domestic probiotic industry [1][5] Group 1: Probiotic Development - YLGB-1496 is the first probiotic strain in the list that is independently developed by a Chinese dairy company and derived from Chinese breast milk [1][5] - The strain is designed to be more compatible with the physical needs of Chinese infants, providing a tailored probiotic solution [1][4] Group 2: Health Benefits - Clinical studies conducted in collaboration with the National Dairy Technology Innovation Center have shown that YLGB-1496 significantly reduces the incidence of eczema and respiratory infections in infants, aiding in the development of their immune systems [5] - The strain has also been proven to enhance gut comfort in infants, reducing the occurrence and severity of diarrhea [5] Group 3: Industrialization and Product Application - Yili's subsidiary, Jinqi Biotechnology, is responsible for the industrialization and commercialization of YLGB-1496, ensuring high-quality and diverse probiotic products for the health food industry [6] - The strain has already been incorporated into several products, including QQ Star's maternal care products and mixed fruit and vegetable juices, with plans for further applications in infant formula [6] Group 4: Future Prospects - The approval of YLGB-1496 signifies a major leap for the Chinese dairy industry from technology following to independent innovation in the probiotic sector [7] - Yili aims to continue its research on the functional properties of the strain and promote the transformation of scientific achievements into products, contributing to the high-quality development of the Chinese dairy industry [7]